中国通号(03969.HK)A股下周一科创板上市预计上半年纯利增6%-15%
中国通号(03969.HK)公布完成A股(688009.SH)发行,将於下周一(22日)在上海证券交易所科创板上市买卖。
科创板企业上市後前5个交易日内,股票交易价格不设涨跌幅限制;上市5个交易日後,涨跌幅限制比例为20%。科创板股票存在股价波动幅度较上海证券交易所主板、深圳证券交易所主板、中小板、创业板更加剧烈的风险。
公司表示,预计2019年上半年实现营业收入204.6亿至219.7亿元人民币(下同),按年增约8.2%-16.2%;归属於上市公司股东的净利润21.1亿至22.8亿元,按年增约6.3%-14.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.